Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LifeStance Health (LFST) EBITDA (2020 - 2025)

LifeStance Health (LFST) has disclosed EBITDA for 6 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 267.79% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 114.85% year-over-year, with the annual reading at $8.7 million for FY2025, 114.85% up from the prior year.
  • EBITDA for Q4 2025 was $11.7 million at LifeStance Health, up from $732000.0 in the prior quarter.
  • The five-year high for EBITDA was $11.7 million in Q4 2025, with the low at -$120.5 million in Q3 2021.
  • Average EBITDA over 5 years is -$37.8 million, with a median of -$35.1 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 3556.71% in 2021, then surged 267.79% in 2025.
  • Over 5 years, EBITDA stood at -$108.0 million in 2021, then soared by 56.89% to -$46.6 million in 2022, then decreased by 1.01% to -$47.0 million in 2023, then skyrocketed by 85.22% to -$7.0 million in 2024, then soared by 267.79% to $11.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $11.7 million, $732000.0, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.